Coronavirus: inside the ‘scrambled’ UK deal for five million Moderna vaccines
Fears over Trump’s ‘vaccine nationalism’ and European supplies led British ministers to prioritise other agreements
![Scientist working on the Moderna coronavirus vaccine](https://cdn.mos.cms.futurecdn.net/u4HGHdzE9iwq3uM8JUC6xQ-415-80.jpg)
As news of another vaccine breakthrough emerged yesterday morning, ministers and civil servants rushed to finalise a deal to buy five million doses - at a cost of £95m.
Although the UK has secured 350 million doses of six Covid-19 jabs, most of which are still undergoing trials, “the Moderna vaccine is not one of those which the government has pre-ordered”, says The Spectator.
The reason, says The Times, is that “large-scale production of the Moderna vaccine is not expected in Europe until April”. As a result, “reaching agreement with other companies that can manufacture more rapidly was prioritised in the hope of starting mass immunisation before the year’s end”.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
![https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg](https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516-320-80.jpg)
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A reluctance to deal with a US company amid “vaccine nationalism” and “concerns over unpredictable behaviour by the US president” also played a part, The Guardian reports. Ministers were reportedly concerned that Donald Trump might commandeer injections before they could be sent to the UK.
Finally, says Politico, the government “wanted to see the Phase 3 results before agreeing a deal”. When those results suggested that the vaccine was 95% effective, ministers and officials “hit Zoom and rushed through an agreement with Moderna”.
The last-minute response had led to “fears that Britain had missed out on supplies”, says The Guardian, especially as “the UK had also shunned the EU vaccine purchase scheme, arguing in July that the government could source vaccines faster on its own”.
That confidence appeared to be justified yesterday, when EU health commissioner Stella Kyriakides said she had “not yet concluded or signed a contract” with Moderna, although “negotiations with the company are ongoing”.
Aside from the Moderna jab, the UK has ordered 40 million doses of the 90% effective Pfizer/BioNTech vaccine - and 100 million doses of the Oxford/AstraZeneca vaccine candidate, which is still in Phase 3 trials.
Ministers “remain hopeful” that the Oxford jab “could be available soon - even by Christmas - with results of that trial reported to be imminent”, says The Guardian.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Holden Frith is The Week’s digital director. He also makes regular appearances on “The Week Unwrapped”, speaking about subjects as diverse as vaccine development and bionic bomb-sniffing locusts. He joined The Week in 2013, spending five years editing the magazine’s website. Before that, he was deputy digital editor at The Sunday Times. He has also been TheTimes.co.uk’s technology editor and the launch editor of Wired magazine’s UK website. Holden has worked in journalism for nearly two decades, having started his professional career while completing an English literature degree at Cambridge University. He followed that with a master’s degree in journalism from Northwestern University in Chicago. A keen photographer, he also writes travel features whenever he gets the chance.
-
Red Speedo: a 'darkly comic' doping drama
The Week Recommends Lucas Hnath's play stars Finn Cole as a 'reptilian' swimmer determined to win at all costs
By Irenie Forshaw, The Week UK Published
-
One Aldwych: where London's creative spirit takes centre stage
The Week Recommends This five-star Covent Garden hotel is the epitome of elegant independence
By Julia O'Driscoll, The Week UK Published
-
Charlotte Dujardin and equestrianism's dark side
In the Spotlight Olympic gold medallist and dressage star's suspension over horse whipping brings abuse in horse sports back into the spotlight
By Harriet Marsden, The Week UK Published
-
Biden tests positive for Covid in fresh blow to campaign
Speed Read The president said he would consider dropping out of the race if presented with a "medical condition"
By Rafi Schwartz, The Week US Published
-
How could J.D. Vance impact the special relationship?
Today's Big Question Trump's hawkish pick for VP said UK is the first 'truly Islamist country' with a nuclear weapon
By Harriet Marsden, The Week UK Published
-
The Tamils stranded on 'secretive' British island in Indian Ocean
Under the Radar Migrants 'unlawfully detained' since 2021 shipwreck on UK-controlled Diego Garcia, site of important US military base
By Harriet Marsden, The Week UK Published
-
'An Everlasting Gobstopper of offense'
Instant Opinion Opinion, comment and editorials of the day
By Justin Klawans, The Week US Published
-
Britain's Labour Party wins in a landslide
Speed Read The Conservatives were unseated after 14 years of rule
By Peter Weber, The Week US Published
-
Will voter apathy and low turnout blight the election?
Today's Big Question Belief that result is 'foregone conclusion', or that politicians can't be trusted, could exacerbate long-term turnout decline
By Harriet Marsden, The Week UK Published
-
Rescuing science from politics
Opinion We need a truly non-partisan Covid Commission that will sift through the story of the pandemic
By Mark Gimein Published
-
Less than total recall
Editor's Letter Why our brains want to forget the darkest days of the pandemic
By Theunis Bates Published